Recruiting
Phase 3

Berobenatide

Sponsor:

Pfizer

Code:

NCT07932925

Conditions

Urinary Incontinence, Stress

Overweight and/or Obesity

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Berobenatide

Placebo

Study Details

Brief summary:

The purpose of this study is to learn about the safety and effectiveness of berobenatide in adult women who have both stress urinary incontinence (SUI) and obesity or overweight.

Participants will be in the study for about 63 weeks

Conditions

Urinary Incontinence, Stress

Overweight and/or Obesity

Study ID

NCT07932925

Start date

Nov 17, 2026

Status verified date

Nov, 2026

Completion date

Dec 1, 2028

Anticipated

Primary completion date

Oct 13, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult women aged 18 years or older
  • Body mass index (BMI) of 27 kg/m² or greater
  • Have a diagnosis of stress urinary incontinence
  • Willing and able to comply with study procedures

Exclusion Criteria:

  • Have had urinary incontinence surgery
  • Have taken medications (prescribed or over-the counter) intended to promote weight loss within 90 days prior to randomization
  • Have recently received onabotulinumtoxin A (Botox) bladder injections or currently taking medications for urinary incontinence
  • History of acute or chronic pancreatitis
  • Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN-2)
  • Have diabetes or laboratory assessments indicative of diabetes
  • Have had a cardiovascular health condition within 90 days prior to randomization
  • Are breastfeeding, pregnant, parturition in the past 12 months, planning to become pregnant in the following 12 months, or of childbearing potential and not using adequate contraception

Study Design

Enrollment

900 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Arm 1

Participants will receive Berobenatide administered according to the study dosing regimen

placebo comparator: Arm 2

Participants will receive placebo administered according to the study dosing regimen

Interventions

Berobenatide

Berobenatide administered by subcutaneous injection

Placebo

Placebo administered by subcutaneous injection

Primary outcome measure

  • Change From Baseline in Stress Incontinence Episode Frequency (IEF) [ Time Frame: Baseline, Week 52 ]

Central Contacts and Locations

Central contacts

Locations

Madison Imaging Center

Recruiting

Citrus Heights, California, United States, 95610

Northern California Research

Recruiting

Sacramento, California, United States, 95821

Hawthorne Health - Boynton Beach, FL

Recruiting

Boynton Beach, Florida, United States, 33436

New Age Medical Research Corporation

Recruiting

Miami, Florida, United States, 33186

Hawthorne Health - Horsham, PA

Recruiting

Horsham, Pennsylvania, United States, 19044

Clinical Trial Network

Recruiting

Houston, Texas, United States, 77074

More Information

Sponsor

Pfizer

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • Stress Urinary Incontinence
  • Obesity
  • Overweight
  • Berobenatide
  • Glucagon-Like Peptide 1 Receptor Agonists
  • Weight Loss
  • Urinary Incontinence
  • Urination Disorders
  • Female Urinary Incontinence

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Pfizer on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.